12/18
08:03 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.
12/16
07:10 am
kalv
KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]
Medium
Report
KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]
12/16
07:00 am
kalv
KalVista Appoints Jeb Ledell as Chief Operating Officer
Medium
Report
KalVista Appoints Jeb Ledell as Chief Operating Officer
12/9
10:18 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/6
08:13 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
12/5
12:25 pm
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Low
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
12/5
06:42 am
kalv
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update [Yahoo! Finance]
12/5
06:30 am
kalv
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
Low
Report
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
12/4
06:30 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26
07:05 am
kalv
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors [Yahoo! Finance]
11/26
07:00 am
kalv
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
Low
Report
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
11/12
06:30 am
kalv
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Medium
Report
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
11/5
06:30 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/4
07:20 am
kalv
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals [Yahoo! Finance]
Medium
Report
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals [Yahoo! Finance]
11/4
07:05 am
kalv
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
Medium
Report
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
11/4
07:00 am
kalv
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
Medium
Report
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
10/28
06:30 am
kalv
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
Medium
Report
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
10/18
06:30 am
kalv
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Medium
Report
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
10/18
06:22 am
kalv
Togo suspends Russia's ride-hailing app Yango [Yahoo! Finance Canada]
Medium
Report
Togo suspends Russia's ride-hailing app Yango [Yahoo! Finance Canada]
10/7
08:17 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
10/4
12:29 pm
kalv
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
Low
Report
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
10/2
06:30 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/30
06:30 am
kalv
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
Medium
Report
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
9/26
06:30 am
kalv
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
Low
Report
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)